1.73 0.02 (1.17%) | 02-14 16:00 | |||||||||||||
|
|
Short term | ![]() |
|||
Mid term | ![]() |
|||
Targets | 6-month : | 2.34 | 1-year : | 2.7 |
Resists | First : | 2 | Second : | 2.31 |
Pivot price | 1.75 ![]() |
|||
Supports | First : | 1.5 | Second : | 1.24 |
MAs | MA(5) : | 1.65 ![]() |
MA(20) : | 1.84 ![]() |
MA(100) : | 2.23 ![]() |
MA(250) : | 2.38 ![]() |
|
MACD | MACD : | -0.2 ![]() |
Signal : | -0.2 ![]() |
%K %D | K(14,3) : | 34.5 ![]() |
D(3) : | 24.4 ![]() |
RSI | RSI(14): 39.1 ![]() |
|||
52-week | High : | 11.18 | Low : | 1.09 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ GOVX ] has closed above bottom band by 44.6%. Bollinger Bands are 45.7% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 1 bars. This is a sign that the market may be about to initiate a new trend.
If tomorrow: | Open lower | Open higher |
High: | 1.76 - 1.76 | 1.76 - 1.77 |
Low: | 1.63 - 1.64 | 1.64 - 1.65 |
Close: | 1.71 - 1.73 | 1.73 - 1.74 |
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; Centers for Disease Control and Prevention; U.S. Department of Defense; Emory University; University of Pittsburgh; and the Burnet Institute. GeoVax Labs, Inc. was incorporated in 1988 and is based in Smyrna, Georgia.
Mon, 09 Dec 2024
GeoVax Labs Secures Key Cancer Vaccine Patent, Reports Breakthrough 100% Tumor Prevention Data - StockTitan
Tue, 19 Nov 2024
GeoVax's COVID Booster Shows Promise in Leukemia Patients, Outperforms mRNA Vaccine - StockTitan
Wed, 13 Nov 2024
Geovax Labs Inc (GOVX) Q3 2024 Earnings Call Highlights: Strategic Advances and Financial Challenges - Yahoo Finance
Tue, 12 Nov 2024
GeoVax Q3 Loss Narrows to $5.8M as BARDA Contract Boosts Revenue to $2.8M - StockTitan
Tue, 12 Nov 2024
GeoVax Reports Third Quarter 2024 Financial Results and Provides Business Update - GlobeNewswire
Mon, 11 Nov 2024
This GeoVax Labs Analyst Begins Coverage On A Bullish Note; Here Are Top Initiations For Monday - Benzinga
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 0 (M) |
Shares Float | 9 (M) |
Held by Insiders | 5.24e+006 (%) |
Held by Institutions | 0.5 (%) |
Shares Short | 301 (K) |
Shares Short P.Month | 0 (K) |
EPS | -2.716e+007 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 0 |
Profit Margin | 0 % |
Operating Margin | -1 % |
Return on Assets (ttm) | 683.6 % |
Return on Equity (ttm) | -134.4 % |
Qtrly Rev. Growth | 300680 % |
Gross Profit (p.s.) | 0 |
Sales Per Share | -116.53 |
EBITDA (p.s.) | -6.93891e+006 |
Qtrly Earnings Growth | -8.4 % |
Operating Cash Flow | 0 (M) |
Levered Free Cash Flow | -23 (M) |
PE Ratio | -0.01 |
PEG Ratio | 0 |
Price to Book value | 0 |
Price to Sales | -0.02 |
Price to Cash Flow | 1.84 |
Dividend | 0 |
Forward Dividend | 301020 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |